Pilot study evaluating nicotinamide in metastatic brain tumors treated with radiation

Julianna Pisch, Brij M. Sood, Alan Alfieri, Anthony M. Berson, Manjeet Chadha, Bhadrasain Vikram

Research output: Contribution to journalArticle

Abstract

Nicotinamide (NAM) has been shown to be an effective radiosensitizer in animal studies, but to date no clinical studies have substantiated this effect. Twenty‐nine patients with brain metastases were randomized to receive NAM and external radiation therapy (RT) (n = 14) or irradiation alone (n = 15). NAM was started on day 1 at 3 g/day and continued until radiation was completed. The RT dose to the whole brain was 30 Gy in 10 fractions in 12–14 days. To evaluate response, a computed tomographic (CT) scan of the head was repeated 1 month post‐treatment. Toxicity was graded from the skin, liver, and gastrointestinal tract. There were no toxicities observed at 39.0 g total dose of NAM. Median survival for the 29 patients, calculated by the Kaplan‐Meier method, was 3.5 months for the NAM + RT group (14 patients) and 3.9 months for the RT alone group (15 patients). Eighteen patients were evaluable for 1 month tumor response by CT scan. Response rates were compared with Fisher's exact two‐tailed test. There was no difference in complete response (CR) (P = 0.62) or CR + partial response (PR) (P = 1.000) between the two groups. Adjuvant NAM, given in doses of 3.0 g/day (39.0 g total dose) in the treatment of brain metastases, has shown no benefit in survival or response in this preliminary Study. © 1994 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)292-296
Number of pages5
JournalRadiation Oncology Investigations
Volume1
Issue number5
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

nicotinamide
Niacinamide
Brain Neoplasms
brain
tumors
Radiation
radiation
Radiotherapy
radiation therapy
dosage
metastasis
Brain
toxicity
Neoplasm Metastasis
Survival
Gastrointestinal Tract
liver
animals
Head
Skin

Keywords

  • brain metastases
  • hypoxic sensitizer
  • nicotinamide

ASJC Scopus subject areas

  • Radiation
  • Radiological and Ultrasound Technology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Pisch, J., Sood, B. M., Alfieri, A., Berson, A. M., Chadha, M., & Vikram, B. (1993). Pilot study evaluating nicotinamide in metastatic brain tumors treated with radiation. Radiation Oncology Investigations, 1(5), 292-296. https://doi.org/10.1002/roi.2970010507

Pilot study evaluating nicotinamide in metastatic brain tumors treated with radiation. / Pisch, Julianna; Sood, Brij M.; Alfieri, Alan; Berson, Anthony M.; Chadha, Manjeet; Vikram, Bhadrasain.

In: Radiation Oncology Investigations, Vol. 1, No. 5, 1993, p. 292-296.

Research output: Contribution to journalArticle

Pisch, J, Sood, BM, Alfieri, A, Berson, AM, Chadha, M & Vikram, B 1993, 'Pilot study evaluating nicotinamide in metastatic brain tumors treated with radiation', Radiation Oncology Investigations, vol. 1, no. 5, pp. 292-296. https://doi.org/10.1002/roi.2970010507
Pisch, Julianna ; Sood, Brij M. ; Alfieri, Alan ; Berson, Anthony M. ; Chadha, Manjeet ; Vikram, Bhadrasain. / Pilot study evaluating nicotinamide in metastatic brain tumors treated with radiation. In: Radiation Oncology Investigations. 1993 ; Vol. 1, No. 5. pp. 292-296.
@article{39828d7fbc034957a3c6aae69f0e38dc,
title = "Pilot study evaluating nicotinamide in metastatic brain tumors treated with radiation",
abstract = "Nicotinamide (NAM) has been shown to be an effective radiosensitizer in animal studies, but to date no clinical studies have substantiated this effect. Twenty‐nine patients with brain metastases were randomized to receive NAM and external radiation therapy (RT) (n = 14) or irradiation alone (n = 15). NAM was started on day 1 at 3 g/day and continued until radiation was completed. The RT dose to the whole brain was 30 Gy in 10 fractions in 12–14 days. To evaluate response, a computed tomographic (CT) scan of the head was repeated 1 month post‐treatment. Toxicity was graded from the skin, liver, and gastrointestinal tract. There were no toxicities observed at 39.0 g total dose of NAM. Median survival for the 29 patients, calculated by the Kaplan‐Meier method, was 3.5 months for the NAM + RT group (14 patients) and 3.9 months for the RT alone group (15 patients). Eighteen patients were evaluable for 1 month tumor response by CT scan. Response rates were compared with Fisher's exact two‐tailed test. There was no difference in complete response (CR) (P = 0.62) or CR + partial response (PR) (P = 1.000) between the two groups. Adjuvant NAM, given in doses of 3.0 g/day (39.0 g total dose) in the treatment of brain metastases, has shown no benefit in survival or response in this preliminary Study. {\circledC} 1994 Wiley‐Liss, Inc.",
keywords = "brain metastases, hypoxic sensitizer, nicotinamide",
author = "Julianna Pisch and Sood, {Brij M.} and Alan Alfieri and Berson, {Anthony M.} and Manjeet Chadha and Bhadrasain Vikram",
year = "1993",
doi = "10.1002/roi.2970010507",
language = "English (US)",
volume = "1",
pages = "292--296",
journal = "Radiation Oncology Investigations",
issn = "1065-7541",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Pilot study evaluating nicotinamide in metastatic brain tumors treated with radiation

AU - Pisch, Julianna

AU - Sood, Brij M.

AU - Alfieri, Alan

AU - Berson, Anthony M.

AU - Chadha, Manjeet

AU - Vikram, Bhadrasain

PY - 1993

Y1 - 1993

N2 - Nicotinamide (NAM) has been shown to be an effective radiosensitizer in animal studies, but to date no clinical studies have substantiated this effect. Twenty‐nine patients with brain metastases were randomized to receive NAM and external radiation therapy (RT) (n = 14) or irradiation alone (n = 15). NAM was started on day 1 at 3 g/day and continued until radiation was completed. The RT dose to the whole brain was 30 Gy in 10 fractions in 12–14 days. To evaluate response, a computed tomographic (CT) scan of the head was repeated 1 month post‐treatment. Toxicity was graded from the skin, liver, and gastrointestinal tract. There were no toxicities observed at 39.0 g total dose of NAM. Median survival for the 29 patients, calculated by the Kaplan‐Meier method, was 3.5 months for the NAM + RT group (14 patients) and 3.9 months for the RT alone group (15 patients). Eighteen patients were evaluable for 1 month tumor response by CT scan. Response rates were compared with Fisher's exact two‐tailed test. There was no difference in complete response (CR) (P = 0.62) or CR + partial response (PR) (P = 1.000) between the two groups. Adjuvant NAM, given in doses of 3.0 g/day (39.0 g total dose) in the treatment of brain metastases, has shown no benefit in survival or response in this preliminary Study. © 1994 Wiley‐Liss, Inc.

AB - Nicotinamide (NAM) has been shown to be an effective radiosensitizer in animal studies, but to date no clinical studies have substantiated this effect. Twenty‐nine patients with brain metastases were randomized to receive NAM and external radiation therapy (RT) (n = 14) or irradiation alone (n = 15). NAM was started on day 1 at 3 g/day and continued until radiation was completed. The RT dose to the whole brain was 30 Gy in 10 fractions in 12–14 days. To evaluate response, a computed tomographic (CT) scan of the head was repeated 1 month post‐treatment. Toxicity was graded from the skin, liver, and gastrointestinal tract. There were no toxicities observed at 39.0 g total dose of NAM. Median survival for the 29 patients, calculated by the Kaplan‐Meier method, was 3.5 months for the NAM + RT group (14 patients) and 3.9 months for the RT alone group (15 patients). Eighteen patients were evaluable for 1 month tumor response by CT scan. Response rates were compared with Fisher's exact two‐tailed test. There was no difference in complete response (CR) (P = 0.62) or CR + partial response (PR) (P = 1.000) between the two groups. Adjuvant NAM, given in doses of 3.0 g/day (39.0 g total dose) in the treatment of brain metastases, has shown no benefit in survival or response in this preliminary Study. © 1994 Wiley‐Liss, Inc.

KW - brain metastases

KW - hypoxic sensitizer

KW - nicotinamide

UR - http://www.scopus.com/inward/record.url?scp=84982730385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982730385&partnerID=8YFLogxK

U2 - 10.1002/roi.2970010507

DO - 10.1002/roi.2970010507

M3 - Article

AN - SCOPUS:84982730385

VL - 1

SP - 292

EP - 296

JO - Radiation Oncology Investigations

JF - Radiation Oncology Investigations

SN - 1065-7541

IS - 5

ER -